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Plevated Placental Growth Factor
evels Are Associated With Adverse
utcomes at Four-Year Follow-Up in
atients With Acute Coronary Syndromes
imo Lenderink, MD,*† Christopher Heeschen, MD,‡ Stephan Fichtlscherer, MD,§
tefanie Dimmeler, MD,§ Christian W. Hamm, MD, Andreas M. Zeiher, MD,§
aarten L. Simoons, MD,* Eric Boersma, PHD,* for the CAPTURE Investigators
eerlen and Rotterdam, the Netherlands; and Munich, Frankfurt, and Bad Neuheim, Germany
OBJECTIVES This study sought to evaluate the predictive value of baseline placental growth factor (PlGF)
for long-term cardiovascular events in acute coronary syndromes (ACS).
BACKGROUND A biomarker of vascular inflammation, PlGF is identified as a powerful predictor for
short-term outcome in patients with ACS.
METHODS In 544 patients who were enrolled in the placebo arm of the c7E3 Fab Anti Platelet Therapy
in Unstable REfractory angina (CAPTURE) trial, PlGF levels were determined as well as
markers of myocardial necrosis (troponin T [TnT]), general inflammation (high-sensitivity
C-reactive protein [hsCRP]), and platelet activation (soluble CD40 ligand [sCD40L]). Cox
proportional hazard regression analyses were applied to evaluate the relationship between
biomarkers and the occurrence of all-cause death or non-fatal myocardial infarction during a
median follow-up period of four years.
RESULTS Patients with PlGF levels in the fourth and fifth quintile (27 ng/l) had higher mortality
than those with lower levels (10.8% vs. 3.2%; hazard ratio [HR], 3.3; 95% confidence interval
[CI], 1.6 to 7.1), as well as a higher incidence of the composite end point of death or
myocardial infarction (27.6% vs. 11.3% events; HR, 2.6; 95% CI, 1.7 to 3.9). The relationship
between PlGF and the composite end point remained significant after adjustment for TnT,
sCD40L, and hsCRP (adjusted HR, 3.3; 95% CI, 2.0 to 5.4).
CONCLUSIONS In patients with ACS, elevated plasma levels of PlGF are associated with adverse cardiac
outcomes during long-term follow-up. These data suggest that PlGF as a more specific
marker of vascular inflammation should be considered for risk stratification of patients with
ACS rather than general markers of inflammation. (J Am Coll Cardiol 2006;47:307–11)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.063© 2006 by the American College of Cardiology Foundation
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bascular inflammation is now believed to play an important
ole in atherosclerosis (1). Markers of general inflammation
uch as high-sensitivity C-reactive protein (hsCRP) (2),
nterleukin-6 (3), and serum amyloid (4) are associated with
dverse outcomes in patients with coronary heart disease.
owever, placental growth factor (PlGF), a member of the
ascular endothelial growth factor (VEGF) family, was
ecently shown to be strongly up-regulated in early and
dvanced atherosclerotic lesions. Increasing evidence sug-
ests that PlGF acts as a primary inflammatory instigator of
therosclerotic plaque instability (5). Indeed, recently it has
een shown that PlGF is an independent biomarker of
hort-term adverse outcome in patients with chest pain that
s suspicious for an acute coronary syndrome (ACS) (6).
Inflammatory processes of atherosclerosis are sustained
fter acute interventional or medical treatment and trigger
From the *Department of Cardiology, Atrium Medical Centre, Heerlen, the
etherlands; †Department of Cardiology, Thoraxcenter, Erasmus Medical Center
otterdam, Rotterdam, the Netherlands; ‡Department of Surgery, Ludwig-
aximilians-University, Munich, Germany; §Department of Cardiology, J. W.
oethe University, Frankfurt, Germany; and the Department of Cardiology,
erckhoff Heart Center, Bad Neuheim, Germany. The CAPTURE study was
upported by Centocor B. V., Leiden, the Netherlands.u
Manuscript received April 10, 2005; revised manuscript received July 7, 2005,
ccepted August 9, 2005.ardiovascular events during long-term follow-up (7,8).
herefore, we studied the relationship between baseline
evels of PlGF and the incidence of all-cause mortality or
on-fatal myocardial infarction during a four-year
ollow-up in ACS patients who were enrolled in the
APTURE trial. We related our findings to other markers,
or example, one of general inflammation, such as hsCRP
nd soluble CD40 ligand (sCD40L).
ETHODS
atients and treatment. The c7E3 Fab Anti Platelet
herapy in Unstable REfractory angina (CAPTURE) pro-
ocol has been described in detail (9). Briefly, patients were
ligible if they had refractory unstable angina, defined as
hest pain at rest with concomitant electrocardiographic
bnormalities compatible with myocardial ischemia (ST-
egment depression, ST-segment elevation, or T-wave in-
ersion), and one or more episodes of typical chest pain or
lectrocardiographic abnormalities during at least 2 h of
reatment with intravenous heparin and nitrates. The most
ecent ischemic episode should have occurred within 48 h
efore enrolment, corresponding to Braunwald class III
nstable angina. All patients had undergone coronary an-
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Placental Growth Factor and Four-Year Outcome in ACS January 17, 2006:307–11iography, and percutaneous coronary intervention was
cheduled within 18 to 24 h after the start of the study
edication. After giving informed consent, patients were
andomly assigned to abciximab (ReoPro, Centocor B.V.,
eiden, the Netherlands; 0.25-mg/kg bolus plus 10 g/min
ontinuous infusion) or placebo. Study medication was
tarted within 2 h of randomization and continued until 1 h
fter the procedure. All patients received aspirin, heparin,
nd nitrates, whereas beta-blockers, calcium channel antag-
nists, and other cardiovascular drugs were given at the
iscretion of the investigator.
nalytical techniques. Plasma samples drawn at the time
f randomization were available for determination of tro-
onin T (TnT), hsCRP, sCD40L, and PlGF. Because TnT
10,11) and sCD40L (12) have been shown to interact with
he treatment effect of abciximab, the present analysis was
estricted to the 544 patients receiving placebo in whom
lood samples were available (86% of patients receiving
lacebo). Blood samples were collected a mean of 8.7 h
standard deviation, 4.9) after the onset of symptoms, but
efore percutaneous coronary intervention and before the
ncidence of adverse events. Measurement of cardiac marker
evels was performed blinded to the patients’ histories.
evels of PlGF and sCD40L were measured by enzyme-
inked immunosorbent assay (both from R&D Systems,
iesbaden, Germany). Total imprecision (expressed as
oefficient of variation) for PlGF was 7.3%. For sCD40L, a
iagnostic threshold level of 5.0 g/l was used. Levels of
nT were determined using a one-step enzyme immuno-
ssay based on electrochemiluminescence technology
Roche Diagnostics, Mannheim, Germany). A diagnostic
hreshold value of 0.01 /l was used. Levels of hsCRP were
easured using the Behring BN II Nephelometer (Dade
ehring, Deerfield, Illinois). A diagnostic threshold value of
0 mg/l was used.
A cut-off value for PlGF of 27 ng/l was used in this study
ased on the difference of number of events between the
hird and fourth quintile (see the Results section), which
as almost equal to the 25 ng/l based on additional
eceiver-operating characteristic analyses and looking at the
aximal sum of sensitivity and specificity per 1 ng/l.
tudy end points. End points of the present analysis were
ll-cause mortality and the composite of all-cause mortality
nd non-fatal myocardial infarction. Follow-up at six
onths was part of the study protocol. Myocardial infarc-
ion during the index hospitalization was defined by creatine
inase (CK)-MB or CK levels exceeding three times the
Abbreviations and Acronyms
ACS  acute coronary syndrome
hsCRP  high-sensitivity C-reactive protein
PlGF  placental growth factor
sCD40L  soluble CD40 ligand
TnT  troponin Tpper limit of normal in two samples and an increase by
n
s0% over the previous value, or an electrocardiogram
ECG) with new significant Q waves in two or more
ontiguous leads. Myocardial infarction after discharge was
efined by CK-MB or CK levels exceeding two times the
pper limit of normal or new significant Q waves in two or
ore contiguous leads. A clinical end point committee
djudicated these events. Survival status and information on
yocardial infarction were collected for the patients who
ere alive six months after randomization. Follow-up data
ere obtained from the treating physician, the general
ractitioner, the patient, or municipal registries and were
ot adjudicated.
ata analysis. Continuous variables were summarized by
edian values with corresponding 25th and 75th percen-
iles. Discrete variables were summarized in terms of fre-
uencies and percentages. Kaplan-Meier analyses were per-
ormed to evaluate the incidence of events over time.
nivariable and multivariable Cox proportional hazards
egression analyses were applied to evaluate the relationship
etween PlGF and long-term outcome. We adjusted for
ge, gender, history of diabetes, and ST-segment depression
n the qualifying ECG and the biomarkers sCD40L,
sCRP, and TnT (thresholds were: 5.0 g/l, 10 mg/l,
nd 0.01 g/l, respectively). The p values were two-sided,
ith p  0.05 being considered significant.
The main results are presented for 544 patients who
ntered the trial. Additional analyses were performed in the
ubgroup of patients who survived the first six months, with
vents counted after this period.
ESULTS
atients with PlGF levels above 27 ng/l had significantly
igher levels of hsCRP than those with lower PlGF levels
64.7% vs. 26.2%, p  0.0001). Also, patients with elevated
lGF levels more often had a history of smoking (47.9% vs.
7.5%; p 0.02). Other established risk factors were evenly
istributed over the two PlGF groups.
igure 1. Bar graphs of the calculated annual incidence of death or
on-myocardial infarction according to placental growth factor (PlGF)
tatus grouped in quintiles.
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January 17, 2006:307–11 Placental Growth Factor and Four-Year Outcome in ACSThe median follow-up duration was 48 months (25th and
5th percentile: 38, 55) with 46 (25th and 75th percentile:
8, 54) months of follow-up beyond 30 days. During
ollow-up, 31 patients had died and 60 had experienced a
on-fatal myocardial infarction. A total of 21 deaths and 21
on-fatal myocardial infarctions occurred after 30 days.
Analyses based on quintiles showed a noticeably higher
alculated annual incidence of death and non-fatal myocar-
ial infarction in the fourth and fifth quintiles (Fig. 1).
ong-term mortality of patients with elevated PlGF levels
as 10.8%, compared with 3.2% in those without elevated
lGF levels (crude hazard ratio, 3.3; 95% confidence inter-
al (CI), 1.6 to 7.1; p  0.002) (Fig. 2). The composite end
oints of death and non-fatal myocardial infarction occurred
n 27.6% and 11.3% of patients (crude hazard ratio, 2.6;
5% CI, 1.7 to 3.9; p  0.001) (Fig. 3).
In the patients who survived the first 30 days, the
ncidence of all-cause mortality during extended follow-up
as 8.7% in those with elevated baseline PlGF and 2.6% in
igure 2. Kaplan-Meier curves of death during four-year follow-up accord
r experienced myocardial infarction (MI) before the 30-day follow-up wigure 3. Kaplan-Meier curves of death or myocardial infarction (MI) during fo
anel, 49 patients who died or experienced MI before the 30-day follow-up wehose without elevated PlGF (crude hazard ratio, 3.2; 95%
I, 1.4 to 7.6; p  0.007). The composite end point
ccurred in 16.2% of patients with elevated PlGF levels and
n 5.7% of patients without elevated PlGF levels (crude
azard ratio, 2.9; 95% CI, 1.5 to 5.3; p  0.001).
After adjustment for multiple baseline characteristics and
nT, sCD40L and hsCRP PlGF remained significant
redictors for the incidence of death or myocardial infarc-
ion during the four years after admission (adjusted hazard
atio, 3.0; 95% CI, 1.1 to 7.9; p  0.026; Table 1), as well
s during long-term follow-up in six-month survivors (ad-
usted hazard ratio, 3.3; 95% CI, 2.0 to 5.4; p  0.001)
Table 1).
ISCUSSION
n this study we demonstrate that elevated baseline levels of
lGF, a more specific marker of vascular inflammation, are
ssociated with adverse long-term outcomes in patients with
o placental growth factor status. In the right panel, 49 patients who died
cluded. Dotted line  placental growth factor 27 ng/l.ur-year follow-up according to placental growth factor status. In the right
re excluded. Dotted line  placental growth factor 27 ng/l.
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Placental Growth Factor and Four-Year Outcome in ACS January 17, 2006:307–11CS. The predictive value of PlGF was independent of
sCRP, a biomarker of general inflammation. Interestingly,
aseline PlGF was also associated with an increased risk of
ardiovascular complications during extended follow-up in
atients who survived the first six months.
These data add to the growing evidence showing that
sCRP as a classic systemic acute-phase protein might not
e specific enough for the inflammation process involved in
ascular atherosclerosis (13). Therefore, hsCRP levels col-
ected in ACS patients seem to be less useful as a tool for
ardiovascular risk stratification and patient management.
n contrast, PlGF as a more specific marker of vascular
nflammation providing independent predictive value for
he short-term cardiovascular outcome is not hampered by
he occurrence of an ACS (5,6). We have shown its
sefulness as a determinant of long-term outcome. It is
mportant to note in this respect that the prognostic value of
aseline PlGF was independent of biomarkers of platelet
ctivation (soluble CD40-ligand) and myocardial necrosis
TnT).
We observed both an early divergence of the curves
hortly after onset of symptoms as well as an impressive late
ivergence of the curves after two years of follow-up. These
ndings support the pathophysiological concept of a chronic
vascular) inflammatory basis of atherosclerosis with an
cute superimposed process in the setting of an ACS (14).
he present data suggest that chronic inflammatory pro-
esses in the coronary vessel wall may indeed result in the
epetitive occurrences of cardiovascular events during long-
erm follow-up (1,15,16). In patients with ACS, early
ercutaneous coronary intervention, as performed in the
resent CAPTURE trial, obviously prevents adverse cardiac
vents during short-term (six-month) follow-up. Long-
erm events, however, apparently require a more effective
nd/or specific anti-inflammatory treatment, such as block-
ng of the PlGF receptor or reducing the activity of
irculating PlGF levels by administration of soluble VEGF
eceptor 1 (17). Future studies of anti-inflammatory thera-
ies should assess a potential additional long-term benefit in
able 1. Multivariable Adjusted Hazard Ratios for the Incidence
Variable
T
HR
ge (per yr) 1.04
lacental growth factor 27 ng/l 3.3
oluble CD40 ligand 5.0 g/l 1.6
igh-sensitivity C-reactive protein 10 mg/l 0.9
roponin T 0.01 g/l 1.7
ale gender 0.6
istory of diabetes 1.1
T-segment depression on qualifying electrocardiogram 1.1
Events were counted from randomization until the end of follow-up in all patients.
I-free survivors at 30 days of follow-up.
CI  confidence interval; HR  hazard ratio; MI  myocardial infarction.atients with ACS. The baseline PlGF level may serve as a towerful indicator for the targeted use of anti-inflammatory
herapy in patients at high risk for the rapid progression of
oronary atherosclerosis. Follow-up PlGF levels could then
e used as indicators for the effect of such therapy.
We acknowledge that this investigation has some limita-
ions. First, the long-term follow-up data, which were
btained from multiple sources, were not adjudicated by an
ndependent clinical event committee. Thus, the applied
riteria for myocardial infarction might have differed be-
ween investigators and some events may actually have been
issed. Second, no information is available on long-term
edical treatment (such as statin or angiotensin-converting
nzyme inhibition therapy), which might have influenced
atient outcome. Accordingly, we recognize that there was
nformation bias in our data. However, it is rather unlikely
hat this would have resulted in a differential bias between
atients with or without elevated PlGF levels. In this
espect, it should be emphasized that the investigators who
ollected long-term follow-up (E. B. and T. L.) were
linded to any information on baseline data (including
iomarker levels). Importantly, between patients with high
nd low PlGF levels, there was no difference in the
revalence of hypercholesterolemia, which was the primary
eason for the initiation of statin treatment at the time of
he CAPTURE study. We think therefore that further
rospective studies should be performed using this post-hoc
efined criteria of PlGF elevation and preferably more time
ntervals.
onclusions. In patients with ACS, increased plasma lev-
ls of PlGF are associated with adverse cardiac outcomes
uring long-term follow-up. Placental growth factor as a
arker of vascular inflammation should be considered for
isk stratification in patients with ACS rather than general
arkers of inflammation such as hsCRP.
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eath or Myocardial Infarction During Long-Term Follow-Up
vents (n  91)*
All Patients
(n  544)
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5% CI) p Value HR (95% CI) p Value
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2.0–5.4) 0.001 3.0 (1.4–6.7) 0.006
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